Zimvie Inc. ( (ZIMV) ) has released its Q2 earnings. Here is a breakdown of the information Zimvie Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ZimVie Inc. is a global leader in the life sciences sector, specializing in dental implant solutions. The company is known for its comprehensive portfolio of products designed to support dental tooth replacement and restoration procedures, with a commitment to advancing clinical science and technology.
In its second-quarter 2025 earnings report, ZimVie Inc. announced a definitive agreement to be acquired by ARCHIMED for $19.00 per share in cash. The company reported net sales of $116.7 million from continuing operations, with a net loss of $3.8 million, reflecting a net loss margin of 3.3%. Adjusted EBITDA from continuing operations stood at $17.5 million, with an adjusted EBITDA margin of 15.0%.
Key financial highlights from the quarter include a slight decrease in net sales by 0.1% compared to the previous year, with a constant currency decline of 2.1%. The net loss improved significantly by $5.7 million compared to the same period in 2024. Adjusted net income rose by $3.6 million to $7.2 million, while the adjusted diluted EPS was reported at $0.26.
ZimVie’s pending acquisition by ARCHIMED is expected to close by the end of 2025, subject to customary closing conditions and regulatory approvals. Upon completion, ZimVie will transition to a privately held entity, ceasing its public trading on the NASDAQ. The company has withdrawn its fiscal 2025 guidance due to the acquisition process.
Looking forward, ZimVie remains focused on executing its strategic initiatives and delivering value to its stakeholders, while navigating the transition to becoming a privately held company under ARCHIMED’s ownership.